

10646440 1/08/06

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAplus to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAplus with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 08:13:57 ON 23 JAN 2006

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL

10646440 1/08/06

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:14:13 ON 23 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JAN 2006 HIGHEST RN 872400-03-8
DICTIONARY FILE UPDATES: 20 JAN 2006 HIGHEST RN 872400-03-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10646440.str



chain nodes :
6 7 8 10 11 12

10646440 1/08/06


ring nodes :
1 2 3 4 5
chain bonds :
1-12 3-6 5-10 6-7 6-8 10-11
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-5 1-12 4-5 6-7 6-8 10-11
exact bonds :
1-2 2-3 3-4 3-6 5-10
isolated ring systems :
containing 1 :

G1:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 10:Atom 11:Atom
12:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 08:14:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 62 TO ITERATE

100.0% PROCESSED 62 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

10646440 1/08/06

PROJECTED ITERATIONS: 768 TO 1712
PROJECTED ANSWERS: 33 TO 447

L2 12 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 08:14:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1113 TO ITERATE

100.0% PROCESSED 1113 ITERATIONS 207 ANSWERS
SEARCH TIME: 00.00.01

L3 207 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 166.94 167.15

FILE 'CAPLUS' ENTERED AT 08:14:50 ON 23 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Jan 2006 VOL 144 ISS 5
FILE LAST UPDATED: 22 Jan 2006 (20060122/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 6 L3


=> d ibib abs hitstr tot

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:873795 CAPLUS
 DOCUMENT NUMBER: 141:366217
 TITLE: Preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivatives as antimicrobials
 INVENTOR(S): Renslo, Adam Robert; Gordeev, Mikhail Fedor; Patel, Dinesh Vinodchhai; Gao, Hongwu; Josyula, Vara Prasad; Venkata Nagendra
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, LLC, USA
 SOURCE: PCT Int. Appl., 187 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089943	A1	20041021	WO 2004-1B1135	20040330
WO 2004089943	C1	20050929		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2521685	AA	20041021	CA 2004-2521685	20040330
EP 1615916	A1	20060118	EP 2004-724333	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 2005192325	A1	20050901	US 2004-815589	20040401
PRIORITY APPLN. INFO.:			US 2003-461134P	P 20030409
			WO 2004-1B1135	W 20040330

OTHER SOURCE(S): MARPAT 141:366217
 GI

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [A = oxazolyl, isoxazolyl, etc., n = 0-1; Y = SOO-2, O, amino; Z = formyl, thioformyl, acyl, etc.; W = CH2, CO, oximino, etc.; R1 = H, OH, amino, etc.; R2-3 = H, F; R4-5 = H, Cl, F, Me, NH2, OH; R6-7 = H, alkyl] are prepared. For example, II is prepared in 9 steps from 2-fluoro-4-nitrobenzaldehyde. II has MIC = 4 µg/mL for S. aureus (UCS213). I are antibacterial agents.

IT 777088-40-1P 777088-93-4P 777088-94-5P
 777088-95-6P 777088-96-7P 777088-97-8P
 777088-98-9P 777088-99-0P 777088-00-6P
 777088-01-7P 777088-02-8P 777088-03-9P
 777088-04-0P 777088-05-1P 777088-06-2P
 777088-07-3P 777088-08-4P 777088-09-5P
 777088-21-1P 777088-22-2P 780766-80-5P
 780766-81-6P 780766-82-7P 780766-83-8P
 780766-84-9P 780766-85-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivs. as antimicrobials)

RN 777088-40-1 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 777088-93-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-94-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777088-95-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-96-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-N-ethyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777088-97-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-N-(2-fluoroethyl)-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 777089-98-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-99-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 777089-00-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-01-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 2-oxo-3-[4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-02-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1R,5S)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 777089-03-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1R,5S)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-04-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1R,5S)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-05-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1R,5S)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 NAME)

Absolute stereochemistry.




RN 777089-06-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-07-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 777089-09-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-09-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-21-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1S,5R,6R)-2-oxo-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 780766-81-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1a,5a,6B)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 780766-82-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1a,5a,6B)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 780766-83-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1a,5a,6B)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 777089-22-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1S,5R,6R)-2-oxo-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 780766-80-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1a,5a,6B)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 780766-84-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1a,5a,6B)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-N-ethyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 780766-85-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[(1a,5a,6B)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RR FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004-609963 CAPLUS
 DOCUMENT NUMBER: 141:140424
 TITLE: Preparation of 3-aryl-2-oxo-5-oxazolidinecarboxamides and analogs as antibacterial agents
 INVENTOR(S): Thomas, Richard Charles; Pael, Toni-jos; Barbashyn, Michael Robert; Gordeev, Mikhail Fedor; Luehr, Gary W.; Remslo, Adams Singh; Upinder, Josyula; Vara Prasad Venkata Nagendra
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 169 pp., Cont.-in-part of U.S. Ser. No. 373,286.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004147760	A1	20040729	US 2003-646440	20030822
US 2004044052	A1	20040304	US 2003-373286	20030224
US 6919329	B2	20050719		

PRIORITY APPLN. INFO.: US 2002-359495P P 20020225
 OTHER SOURCE(S): MARPAT 141:140424
 GI

Applicant




AB Title compds. of formula I, II, and III [wherein B = (un)substituted cycloalkyl, cycloalkenyl, aryl, or heterocyclyl; C = (hetero)aryl (un)substituted with 1-3 R2; or BC = (un)substituted bicyclic heterocycle; R1 = H, OH, cycloalkyl, NH2, or (un)substituted alkyl, alkoxy, or alkenyl; R2 = independently H, NH2, NO2, CN, halo, or (un)substituted alkyl; with provisos; and pharmaceutically acceptable salts thereof] were prepared as

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 antibacterial agents. Examples include syntheses and biol. data for 91 compds. For instance, benzyl 3-fluoro-4-(4-morpholinyl)phenylcarbamate was stirred with BuLi in THF at -78° for 30 min. Cycloaddn. with potassium (2R)-glycidate gave the 2-oxo-5-oxazolidinecarboxylic acid, which was amidated using oxalyl chloride and ammonium to afford (R)-(-)-IV. Compds. of the invention inhibited growth of *Staphylococcus aureus* with MIC values ranging from 0.5 µg/mL to 16 µg/mL. Thus, I, II, and III and their pharmaceutical compns. are useful for the treatment of microbial infections.

IT 487041-12-3P, (5R)-(-)-3-[4-(3,6-Dihydro-2H-pyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-18-9P, (5R)-(-)-3-[4-(3,6-Dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide S,S-dioxide 487041-38-3P, (5R)-(-)-3-[3-Fluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide S-oxide 487041-40-7P, (5R)-(-)-3-[3,5-Difluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide S-oxide 590421-69-5P, (5R)-3-[4-(4-Oxo-3,4-dihydro-1(2H)-pyridinyl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (antibacterial agent; preparation of aryloxazolidinecarboxamides and analogs as antibacterial agents)

RN 487041-12-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-2H-pyran-4-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 487041-18-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 487041-38-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-40-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 590421-69-5 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-3-fluorophenyl]-2-oxo-, (5R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 487040-98-2P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 487041-01-0P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-N-methyl-2-oxooxazolidine-5-carboxamide 487041-02-1P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-N-

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
590421-85-5P, (5R)-N-(2-Fluoroethyl)-3-[4-(4-oxo-3,4-dihydro-1(2H)-pyridinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590421-86-5P, (5R)-3-[4-(4-Oxo-3,4-dihydro-1(2H)-pyridinyl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-92-4P, (5R)-N-Methyl-3-[4-(4-oxo-3,4-dihydro-1(2H)-pyridinyl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-94-6P, (5R)-N-Ethyl-3-[4-(4-oxo-3,4-dihydro-1(2H)-pyridinyl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-95-7P, (5R)-3-[3-Fluoro-4-(4-oxo-3,4-dihydro-1(2H)-pyridinyl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 590422-32-5P 590422-33-6P 590422-34-7P 590422-35-8P 590422-36-9P 590422-37-0P 590422-38-1P 590422-39-2P 590422-40-5P 590422-41-6P, (5R)-3-[3-Fluoro-4-(1-imino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-42-7P, (5R)-N-Methyl-3-[3-Fluoro-4-(1-imino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-43-8P, (5R)-3-[3-Fluoro-4-(1-methylimino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-44-9P, (5R)-N-Methyl-3-[3-Fluoro-4-(1-methylimino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-45-0P, (5R)-3-[3,5-difluoro-4-(1-imino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-46-1P, (5R)-N-Methyl-3-[3,5-difluoro-4-(1-imino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-47-2P, (5R)-3-[3,5-difluoro-4-(1-methylimino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-48-3P, (5R)-N-Methyl-3-[3,5-difluoro-4-(1-methylimino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-55-2P, (5R)-3-[3,5-difluoro-4-(1-formyl-3-methylazetidin-3-yl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-56-3P, (5R)-N-Methyl-3-[3,5-difluoro-4-(1-formyl-3-methylazetidin-3-yl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-57-4P, (5R)-3-[3-Fluoro-4-(1-formyl-3-methylazetidin-3-yl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-71-2P 590422-72-3P 590422-73-4P 590422-74-5P 590422-75-6P 590422-76-7P 590422-77-8P 590422-78-9P 591233-29-3P 591233-31-7P 591233-32-9P 591233-35-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (antibacterial agent; prep. of arylloxazolidinecarboxamides and analogs as antibacterial agents)

RN 487040-98-2 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-, (5R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(5R)-(-)-3-[3-(3-Fluoro-4-(4-morpholinyl)phenyl)-N-propyl-2-oxooxazolidine-5-carboxamide 487041-03-2P, (5R)-(-)-3-[3-(3-Fluoro-4-(4-morpholinyl)phenyl)-N-methoxy-2-oxooxazolidine-5-carboxamide 487041-04-3P, (5R)-(-)-3-[3-(3-Fluoro-4-(4-morpholinyl)phenyl)-N-hydroxy-2-oxooxazolidine-5-carboxamide 487041-07-4P, (5R)-(-)-3-[3-(3-Fluoro-4-(4-morpholinyl)phenyl)-2-oxooxazolidine-5-carboxamide 487041-11-2P, (5R)-(-)-3-[3-(3-Fluoro-4-(4-morpholinyl)phenyl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-14-5P, (5R)-(-)-3-[4-(Tetrahydro-2H-pyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-15-6P, (5R)-3-[4-(3-Dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-19-0P, (5R)-(-)-3-[4-(Tetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 5,5-dioxide 487041-20-3P, (5R)-(-)-3-[3-Fluoro-4-(4-hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxooxazolidine-5-carboxamide 487041-26-9P, (5R)-(-)-3-[4-(Thiomorpholin-4-yl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-31-5P, (5R)-(-)-3-[4-(Thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 5,5-dioxide 487041-35-0P, (5R)-(-)-3-[3-Fluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 5,5-dioxide 487041-45-2P, (5R)-(-)-3-[4-(Tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 5,5-dioxide 590420-97-4P, (5R)-(-)-3-[3,5-Difluoro-4-(N-Methyl-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 5,5-dioxide 590420-98-5P, (5R)-(-)-3-[3,5-Difluoro-4-(4-morpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590420-69-6P, (5R)-(-)-N-Methyl-3-[3,5-Difluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 5,5-dioxide 590420-92-1P, (5R)-(-)-3-[3,5-Difluoro-4-(Tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 5,5-dioxide 590421-05-9P, (5R)-3-[4-(5,7-Dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-23-1P, (5R)-3-[4-(5,7-Dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-25-3P, (5R)-N-Methyl-3-[4-(5,7-Dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-31-1P, (5R)-(-)-3-[3,5-Difluoro-4-[1-(methoxycarbonyl)-3-methylazetidin-3-yl]phenyl]-2-oxooxazolidine-5-carboxamide 590421-40-2P, (5R)-(-)-N-Methyl-3-[3,5-Difluoro-4-[1-(methoxycarbonyl)-3-methylazetidin-3-yl]phenyl]-2-oxooxazolidine-5-carboxamide 590421-49-1P, (5R)-3-[3-Fluoro-4-(5-oxo-5,6-dihydro-4H-1,3,4-thiadiazin-2-yl)phenyl]-2-oxooxazolidine-5-carboxamide 590421-57-1P, (5R)-3-[4-(1,1-Dioxido-2,3-dihydro-4H-1,4-thiazin-4-yl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-60-6P, (5R)-3-[4-(2,5-Dihydro-1H-pyrrrol-1-yl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-75-3P, (5R)-N-Methyl-3-[4-(4-Oxo-3,4-dihydro-1(2H)-pyridinyl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-76-4P, (5R)-N-Ethyl-3-[4-(4-Oxo-3,4-dihydro-1(2H)-pyridinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590421-77-5P, (5R)-3-[4-(4-Oxo-3,4-dihydro-1(2H)-pyridinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590421-83-3P, (5R)-N-Methyl-3-[4-(4-Oxo-3,4-dihydro-1(2H)-pyridinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590421-84-4P, (5R)-N-Ethyl-3-[4-(4-Oxo-3,4-dihydro-1(2H)-pyridinyl)phenyl]-2-oxooxazolidine-5-carboxamide




RN 487041-01-0 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-N-methyl-2-oxo-, (5R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-02-1 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-N-2-propenyl-, (5R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-03-2 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-N-propyl-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-04-3 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-N-methoxy-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-05-4 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-N-hydroxy-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-07-6 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(3-pyridinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-11-2 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-pyridinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-15-6 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 487041-14-5 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(tetrahydro-2H-pyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-19-0 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-20-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-26-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)




RN 487041-28-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(4-morpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-31-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)




RN 487041-35-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-45-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 2-oxo-3-[4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590420-87-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590420-88-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(4-morpholinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590420-89-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590420-92-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590420-94-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-05-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590421-07-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590421-09-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-23-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-25-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-26-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(cis-tetrahydro-1-imino-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-31-1 CAPLUS
 CN 1-Azetidinecarboxylic acid, 3-[4-((5R)-5-(aminocarbonyl)-2-oxo-3-oxazolidinyl)-2,6-difluorophenyl]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590421-40-2 CAPLUS
 CN 1-Azetidinecarboxylic acid, 3-[2,6-difluoro-4-((5R)-5-(methylamino)carbonyl)-2-oxo-3-oxazolidinyl]phenyl]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590421-49-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-((5,6-dihydro-5-oxo-4H-1,3,4-thiadiazin-2-yl)-3-fluorophenyl)-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-57-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-((2,3-dihydro-1,1-dioxido-4H-1,4-thiazin-4-yl)-3,5-difluorophenyl)-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-60-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-((2,5-dihydro-1H-pyrrol-1-yl)-3,5-difluorophenyl)-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-75-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-((3,4-dihydro-4-oxo-1(2H)-pyridinyl)-3-fluorophenyl)-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-76-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-((3,4-dihydro-4-oxo-1(2H)-pyridinyl)-3-fluorophenyl)-N-ethyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-77-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-83-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)




RN 590421-84-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)phenyl]-N-ethyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-85-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)phenyl]-N-(2-fluoroethyl)-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-86-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-92-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-3,5-difluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-93-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-3,5-difluorophenyl]-N-ethyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-94-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-3,5-difluorophenyl]-N-(2-hydroxyimino)-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 590422-10-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 590422-32-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(cis-1,1,3,4,5,6-hexahydro-1-methylimino)-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)


RN 590422-34-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(cis-1,1,3,4,5,6-hexahydro-1-methylimino)-1-oxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-35-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(trans-1,1,3,4,5,6-hexahydro-1-imino-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.




RN 590422-33-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(cis-1,1,3,4,5,6-hexahydro-1-imino-1-oxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-36-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(trans-1,1,3,4,5,6-hexahydro-1-imino-1-oxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 590422-37-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(trans-1,1,3,4,5,6-hexahydro-1-imino-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 590422-38-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[trans-1,1,3,4,5,6-hexahydro-1-(methylimino)-1-oxido-2H-thiopyran-4-yl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 590422-39-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 590422-40-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 590422-41-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-imino-1-oxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



RN 590422-42-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-imino-1-oxido-4-thiomorpholinyl)-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 590422-44-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-(methylimino)-1-oxido-4-thiomorpholinyl)-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-45-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-imino-1-oxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 590422-43-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-(methylimino)-1-oxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-46-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-imino-1-oxido-4-thiomorpholinyl)-3,5-difluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-47-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-(methylimino)-1-oxido-4-thiomorpholinyl)-3,5-difluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 590422-56-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(1-formyl-3-methyl-3-azetidinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 590422-57-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1-formyl-3-methyl-3-azetidinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 590422-48-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-(methylimino)-1-oxido-4-thiomorpholinyl)-3,5-difluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-55-2 CAPLUS



RN 590422-58-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1-formyl-3-methyl-3-azetidinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-71-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(1,2,3,6-tetrahydro-1-((2S)-2-hydroxy-1-oxo-3-(phosphonoxy)propyl)-4-pyridinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10646440 1/08/06

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



PAGE 2-A



PAGE 2-A

RN 590422-72-3 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-[(2S)-2-hydroxy-1-oxo-3-(phosphonoxy)propyl]-4-pyridinyl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 590422-73-4 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[4-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)



PAGE 2-A



PAGE 2-A

RN 590422-74-5 CAPLUS



CN 5-Oxazolidinecarboxamide, 3-[4-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 590422-75-6 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-[(2S)-2-hydroxy-1-oxo-3-(phosphonoxy)propyl]-4-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 590422-76-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1,2,3,6-tetrahydro-1-[(2S)-2-hydroxy-1-oxo-3-(phosphonoxy)propyl]-4-pyridinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 590422-77-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-{1-[(2S)-2,3-dihydroxy-1-oxopropyl]-4-pyridinyl}-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-78-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-{1-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl}-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 591233-29-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591233-31-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 591233-33-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 2-oxo-3-[4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)



RN 591233-35-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 2-oxo-3-[4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 487041-06-5P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-N-benzyl-2-oxooxazolidine-5-carboxamide 487041-17-8P, (5R)-(-)-3-[4-(3,6-Dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 oxooxazolidine-5-carboxamide 487041-21-4P, (-)-Phenylmethyl 4-[4-((5R)-5-(aminocarbonyl)-2-oxo-3-oxazolidinyl)-2-fluorophenyl]-1-piperazinecarboxylate 487041-24-7P, (5R)-3-[3-Fluoro-4-[4-(phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-2-oxooxazolidine-5-carboxamide 487041-25-8P, (5R)-3-[3-Fluoro-4-(piperazin-1-yl)phenyl]-2-oxooxazolidine-5-carboxamide
 RL: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT (Reactant or reagent)
 (intermediate) prep. of aryl oxazolidinecarboxamides and analogs as antibacterial agents
 RN 487041-06-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-N-(phenylmethoxy)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-17-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-21-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[4-((5R)-5-(aminocarbonyl)-2-oxo-3-oxazolidinyl)-2-fluorophenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-24-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[4-(phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 487041-25-8 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-,
(SR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 725261-08-5P 725261-09-6P, (SR)-N-Methyl-3-[3-Fluoro-4-
(6-(1-methyl-1H-tetrazol-5-yl)pyridin-3-yl)phenyl]-2-oxooxazolidine-5-
carboxamide 725261-10-9P, (SR)-N-Methyl-3-[3-Fluoro-4-
(6-
(1,2,4)triazol-1-yl)pyridin-3-yl)phenyl]-2-oxooxazolidine-5-carboxamide

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
725261-11-0P, (SR)-3-[3-Fluoro-4-
(6-
(1,2,4)triazol-1-yl)pyridin-3-yl]phenyl]-
2-oxooxazolidine-5-carboxamide 725261-12-1P,
(SR)-3-[3-Fluoro-4-
(6-(5-methyl-1-
(1,2,4)triazol-3-yl)pyridin-3-yl)phenyl]-
2-oxooxazolidine-5-carboxamide 725261-13-2P,
(SR)-N-Methyl-3-[3-Fluoro-4-
(6-(5-methyl-1-
(1,2,4)triazol-3-yl)pyridin-3-yl)phenyl]-
2-oxooxazolidine-5-carboxamide 725261-14-3P,
(SR)-N-Methyl-3-[3-Fluoro-4-
(6-(tetrazol-1-yl)pyridin-3-yl)phenyl]-
2-oxooxazolidine-5-carboxamide 725261-15-4P, (SR)-3-[3-Fluoro-4-
(6-tetrazol-1-yl)pyridin-3-yl)phenyl]-2-oxooxazolidine-5-carboxamide
725261-16-5P, (SR)-3-[3-Fluoro-4-
(6-pyrazol-1-yl)pyridin-3-
y)phenyl]-2-oxooxazolidine-5-carboxamide 725261-17-6P,
(SR)-N-Methyl-3-[3-Fluoro-4-
(6-pyrazol-1-yl)pyridin-3-yl)phenyl]-2-
oxooxazolidine-5-carboxamide 725261-18-7P, (SR)-3-[3-Fluoro-4-
(6-
(1,2,3)triazol-1-yl)pyridin-3-yl)phenyl]-2-oxooxazolidine-5-carboxamide
725261-19-8P, (SR)-3-[3-Fluoro-4-
(6-(5-methyl-1-
(1,3,4)triazol-2-
y)phenyl]-2-oxooxazolidine-5-carboxamide
725261-20-9P, (SR)-N-Methyl-3-[3-Fluoro-4-
(6-(5-methyl-1-
(1,3,4)oxadiazol-2-
y)phenyl]-2-oxooxazolidine-5-carboxamide
725261-21-0P, (SR)-N-Methyl-3-[3-Fluoro-4-
(6-(2-oxooxazolidin-3-
y)phenyl)-2-oxooxazolidine-5-carboxamide
725261-22-3P, (SR)-3-[3-Fluoro-4-
(6-(2-oxooxazolidin-3-
y)phenyl)-2-oxooxazolidine-5-carboxamide 725261-23-4P,
(SR)-3-[3-Fluoro-4-
(6-(2-oximidazolidin-1-yl)pyridin-3-yl)phenyl]-2-
oxooxazolidine-5-carboxamide 725261-24-5P, (SR)-N-Methyl-3-[3-
Fluoro-4-
(6-(2-oximidazolidin-1-yl)pyridin-3-yl)phenyl]-2-oxooxazolidine-5-
carboxamide 725261-25-6P, (SR)-3-[3-Fluoro-4-
(6-(2-oxooxazolidin-3-
y)phenyl)-2-oxooxazolidine-5-carboxamide 725261-26-7P,
(SR)-N-Methyl-3-[3-Fluoro-4-
(6-(2-oxooxazolidin-3-
y)phenyl)-2-oxooxazolidine-5-carboxamide 725261-27-8P, (SR)-N-Methyl-3-[3-
Fluoro-4-
(6-
(1,2,4)triazol-1-yl)pyridin-3-yl)phenyl]-2-oxooxazolidine-5-
carboxamide 725261-28-9P, (SR)-3-[3-Fluoro-4-
(6-
(1,2,4)oxadiazol-3-
y)phenyl]-2-oxooxazolidine-5-carboxamide
725261-29-0P, (SR)-3-[3-Fluoro-4-
(6-(3-methyl-
(1,2,4)oxadiazol-3-
y)phenyl)-2-oxooxazolidine-5-carboxamide
725261-30-3P, (SR)-N-Methyl-3-[3-Fluoro-4-
(6-(3-methyl-
(1,2,4)oxadiazol-3-
y)phenyl)-2-oxooxazolidine-5-carboxamide
725261-31-4P, (SR)-N-Methyl-3-[3-Fluoro-4-
(6-(5-
(1,2,4)triazol-4-
y)phenyl)-2-oxooxazolidine-5-carboxamide
725261-32-5P, (SR)-3-[3-Fluoro-4-
(6-(5-
(1,2,4)triazol-4-
y)phenyl)-2-oxooxazolidine-5-carboxamide
725261-33-6P, (SR)-3-[4-(6-Acetylaminopyridin-3-yl)-3-
fluorophenyl]-2-oxooxazolidine-5-carboxamide 725261-34-7P,
(SR)-N-Methyl-3-[3-Fluoro-4-
(6-(2-hydroxyacetylaminopyridin-3-yl)phenyl)-2-
oxooxazolidine-5-carboxamide 725261-35-8P,
(SR)-3-[3-Fluoro-4-
(6-(2-hydroxyacetylaminopyridin-3-yl)phenyl)-2-
oxooxazolidine-5-carboxamide 725261-36-9P, (SR)-3-[3-Fluoro-4-
(6-(4-hydroxyacetylpirazin-1-yl)pyridin-3-yl)phenyl]-2-oxooxazolidine-5-
carboxamide 725261-37-0P, (SR)-N-Methyl-3-[3-Fluoro-4-
(6-(4-hydroxyacetylpirazin-1-yl)pyridin-3-yl)phenyl]-2-oxooxazolidine-5-
carboxamide 725261-38-1P, (SR)-3-[4-(6-Cyanopiperazin-1-
y)phenyl]-2-oxooxazolidine-5-carboxamide
725261-39-2P, (SR)-N-Methyl-3-[4-(6-(4-Cyanopiperazin-1-
y)phenyl)-2-oxooxazolidine-5-carboxamide 725261-40-5P,
(SR)-N-Methyl-3-[3-Fluoro-4-
(2-(4-hydroxyacetylpirazin-1-yl)pyrimidin-5-
y)phenyl]-2-oxooxazolidine-5-carboxamide 725261-41-6P,

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(SR)-N-Methyl-3-[4-(2-(4-Cyanopiperazin-1-yl)pyrimidin-5-yl)-3-
fluorophenyl]-2-oxooxazolidine-5-carboxamide 725261-42-8P,
(SR)-3-[3-Fluoro-4-
(4-
(3,4,5,6-tetrahydro-1,2'bi)pyridinyl-5-
y)phenyl]-2-oxooxazolidine-5-carboxamide 725261-43-8P,
(SR)-N-Methyl-3-[3-Fluoro-4-
(4-
(3,4,5,6-tetrahydro-1,2'bi)pyridinyl-5-
y)phenyl]-2-oxooxazolidine-5-carboxamide 725261-44-9P
725261-45-0P 725261-46-1P 725261-47-2P
725261-48-3P, (SR)-N-Methyl-3-[3-Fluoro-4-
(1-hydroxyacetyl-1,2,3,6-
tetrahydropyridin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide
725261-49-4P, (SR)-3-[3-Fluoro-4-
(1-hydroxyacetyl-1,2,3,6-
tetrahydropyridin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide
725261-50-5P, (SR)-3-[3-Fluoro-4-
(1-hydroxyacetyl-1,2,3,6-
tetrahydropyridin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide
725261-51-6P, (SR)-3-[3-Fluoro-4-
(1-hydroxyacetyl-1,2,3,6-
tetrahydropyridin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide
725261-52-7P, (SR)-3-[3-Fluoro-4-
(1-hydroxyacetyl-1,2,3,6-
tetrahydropyridin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide
725261-53-8P, (SR)-N-Methyl-3-[3-Fluoro-4-
(1-methylsulfonylacyetyl-1,2,3,6-
tetrahydropyridin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide
725261-54-1P, (SR)-N-Methyl-3-[3-Fluoro-4-
(1-formyl-1,2,3,6-
tetrahydropyridin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide
725261-55-2P, (SR)-3-[3-Fluoro-4-
(1-formyl-1,2,3,6-
tetrahydropyridin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide
725261-56-3P, (SR)-N-Methyl-3-[3-Fluoro-4-
(4-(5-Carbamoyl-2-oxooxazolidin-3-
y)phenyl)-2-
(2-fluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid methylamide
725261-57-4P, (SR)-4-(4-(5-Carbamoyl-2-oxooxazolidin-3-yl)-2-
fluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid amide
725261-58-5P, (SR)-4-(4-(5-Carbamoyl-2-oxooxazolidin-3-yl)-2-
fluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid methylamide
725261-59-6P, (SR)-4-(4-(5-Carbamoyl-2-oxooxazolidin-3-yl)-2-
fluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid methyl ester
725261-60-9P, (SR)-4-(2-Fluoro-4-(5-methylcarbamoyl-2-oxooxazolidin-3-
y)phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid methyl ester
725261-61-0P, (SR)-N-Methyl-3-[4-(1-Cyano-1,2,3,6-
tetrahydropyridin-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide
725261-62-1P, (SR)-3-[4-(1-Cyano-1,2,3,6-
tetrahydropyridin-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 725261-63-2P,
(SR)-3-[3-Fluoro-4-
(1-(methanesulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-2-
fluorophenyl]-2-oxooxazolidine-5-carboxamide 725261-64-3P,
(SR)-N-Methyl-3-[3-Fluoro-4-
(1-(methanesulfonyl)-1,2,3,6-tetrahydropyridin-4-
yl)-2-oxooxazolidine-5-carboxamide 725261-65-4P,
(SR)-N-Methyl-3-[3-Fluoro-4-
(1-pyrimidin-2-yl-1,2,3,6-tetrahydropyridin-4-
yl)-2-oxooxazolidine-5-carboxamide 725261-66-5P,
(SR)-3-[3-Fluoro-4-
(1-(3-oxobutyryl)-1,2,3,6-tetrahydropyridin-4-
yl)-2-oxooxazolidine-5-carboxamide 725261-67-6P,
(SR)-N-Methyl-3-[3-Fluoro-4-
(1-(3-oxobutyryl)-1,2,3,6-tetrahydropyridin-4-
yl)-2-oxooxazolidine-5-carboxamide 725261-68-7P,
(SR)-N-Methyl-3-[3-Fluoro-4-
(1-((methanesulfonyl)amino)acetyl)-1,2,3,6-
tetrahydropyridin-4-yl)-2-oxooxazolidine-5-carboxamide
725261-69-8P, (SR)-3-[3-Fluoro-4-
(1-((methanesulfonyl)amino)acetyl)-1,2,3,6-
tetrahydropyridin-4-yl)-2-oxooxazolidine-5-carboxamide 725261-70-9P,
725261-71-1P 725261-72-3P
725261-73-4P 725261-74-5P 725261-75-6P
725261-76-7P 725261-77-8P
725261-78-9P, (SR)-3-[4-(1,1-Dioxo-1,2-dihydrothiopyran-4-yl)-3,5-
difluorophenyl]-2-oxooxazolidine-5-carboxamide 725261-80-3P,
(SR)-N-Methyl-3-[4-(1,1-Dioxo-1,2-dihydrothiopyran-4-yl)-3,5-
difluorophenyl]-2-oxooxazolidine-5-carboxamide 725261-81-4P,
3-[4-(1,2-Dihydrothiopyran-4-yl)-3,5-difluorophenyl]-2-oxooxazolidine-5-


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
carboxylic acid methylamide 725261-83-6P, 3-[4-(1,1-Dioxo-1,2-
dihydrothiopyran-4-yl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide
725261-85-8P, (SR)-3-[3,5-Difluoro-4-
(tetrahydropyran-4-yl)phenyl]-2-
oxooxazolidine-5-carboxamide 725261-87-0P,
(SR)-N-Methyl-3-[3,5-Difluoro-4-
(tetrahydropyran-4-yl)phenyl]-2-
oxooxazolidine-5-carboxamide 726169-59-1P 726169-60-4P
726169-61-5P 726169-62-6P 726169-63-7P
726169-64-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preps. of 3-aryl-2-oxo-5-oxazolidinecarboxamides and analogs as
antibacterial agents)
RN 725261-08-5 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-
(6-(1-methyl-1H-tetrazol-5-yl)-3-
pyridinyl)phenyl]-2-oxo-, (SR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-09-6 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-
(6-(1-methyl-1H-tetrazol-5-yl)-3-
pyridinyl)phenyl]-N-methyl-2-oxo-, (SR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-10-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(1H-1,2,4-triazol-1-yl)-3-pyridinyl]phenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-11-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(1H-1,2,4-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-12-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(5-methyl-1,2,4-oxadiazol-3-yl)-3-pyridinyl]phenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-13-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(5-methyl-1,2,4-oxadiazol-3-yl)-3-pyridinyl]phenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-14-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(1H-tetrazol-1-yl)-3-pyridinyl]phenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-15-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(1H-tetrazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-16-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(1H-pyrazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-17-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(1H-pyrazol-1-yl)-3-pyridinyl]phenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-18-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(1H-1,2,3-triazol-1-yl)-3-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-19-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-20-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridinyl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-21-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(2-oxo-3-oxazolidinyl)-3-pyridinyl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-22-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(2-oxo-3-oxazolidinyl)-3-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-23-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(2-oxo-1-imidazolidinyl)-3-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-24-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(2-oxo-1-imidazolidinyl)-3-pyridinyl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-25-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[6-(5-oxazolyl)-3-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-26-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(6-(5-oxazolyl)-3-pyridinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-27-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(6-(1,2,4-oxadiazol-3-yl)-3-pyridinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-28-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(6-(1,2,4-oxadiazol-3-yl)-3-pyridinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-29-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(6-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyridinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-30-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(6-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyridinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-31-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[(6-(1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)-3-pyridinyl)-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-32-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[(6-(1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)-3-pyridinyl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725261-33-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[(6-(acetylamino)-3-pyridinyl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 725261-34-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(hydroxyacetyl)amino]-3-pyridinyl]phenyl-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

RN 725261-35-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(hydroxyacetyl)amino]-3-pyridinyl]phenyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A

RN 725261-36-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(hydroxyacetyl)-1-piperazinyl]-3-pyridinyl]phenyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A



PAGE 1-A

PAGE 2-A






PAGE 2-A

RN 725261-37-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(hydroxyacetyl)-1-piperazinyl]-3-pyridinyl]phenyl-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 725261-38-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[(4-cyano-1-piperazinyl)-3-pyridinyl]-3-fluorophenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 725261-39-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[6-(4-cyano-1-piperazinyl)-3-pyridinyl]-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-40-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[2-(4-hydroxyacetyl)-1-piperazinyl]-5-pyrimidinyl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 725261-41-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[6-(4-cyano-1-piperazinyl)-3-pyridinyl]-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725261-42-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[2-(4-hydroxyacetyl)-1-piperazinyl]-5-pyrimidinyl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 725261-43-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(6-(4-oxo-1-piperidinyl)-3-pyridinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 725261-44-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(6-(4-hydroxy-1-piperidinyl)-3-pyridinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-45-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(6-(4-hydroxy-1-piperidinyl)-3-pyridinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 725261-46-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(6-(4-(hydroxymino)-1-piperidinyl)-3-pyridinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-A




PAGE 2-A




RN 725261-47-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(6-hydroxyimino)-1-piperidinyl]-3-pyridinyl]phenyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-48-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1,2,3,6-tetrahydro-1-hydroxyacetyl)-4-pyridinyl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-49-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1,2,3,6-tetrahydro-1-hydroxyacetyl)-4-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-51-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1,2,3,6-tetrahydro-1-(methoxyacetyl)-4-pyridinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-50-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1,2,3,6-tetrahydro-1-(methoxyacetyl)-4-pyridinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-52-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1,2,3,6-tetrahydro-1-(methylthio)acetyl)-4-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725261-53-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1,2,3,6-tetrahydro-1-(methylthio)acetyl)-4-pyridinyl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725261-54-1 CAPLUS


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1-formyl-1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-55-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1-formyl-1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 725261-56-3 CAPLUS
 CN 1(2H)-Pyridinecarboxamide, 4-[4-[(5R)-5-(aminocarbonyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3,6-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-57-4 CAPLUS
 CN 1(2H)-Pyridinecarboxamide, 4-[4-[(5-(aminocarbonyl)-2-oxo-3-oxazolidinyl)-2-fluorophenyl]-3,6-dihydro-, (9CI) (CA INDEX NAME)




RN 725261-58-5 CAPLUS
 CN 1(2H)-Pyridinecarboxamide, 4-[(4-[(5-(aminocarbonyl)-2-oxo-3-oxazolidinyl)-2-


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 fluorophenyl]-3,6-dihydro-N-methyl- (9CI) (CA INDEX NAME)



RN 725261-59-6 CAPLUS
 CN 1(2H)-Pyridinecarboxylic acid, 4-[(4-[(5-(aminocarbonyl)-2-oxo-3-oxazolidinyl)-2-fluorophenyl]-3,6-dihydro-, methyl ester (9CI) (CA INDEX NAME)




RN 725261-60-9 CAPLUS
 CN 1(2H)-Pyridinecarboxylic acid, 4-[(2-fluoro-4-[(5-[(methylamino)carbonyl]-2-oxo-3-oxazolidinyl)phenyl]-3,6-dihydro-, methyl ester (9CI) (CA INDEX NAME)



RN 725261-61-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1-cyano-1,2,3,6-tetrahydro-4-pyridinyl)-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725261-62-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1-cyano-1,2,3,6-tetrahydro-4-pyridinyl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 725261-65-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(2-pyridinyl)-4-pyridinyl]phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-63-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(methylsulfonyl)-4-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-64-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-




RN 725261-66-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,3-dioxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-67-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-{1-(1,3-dioxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl}-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-68-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1,2,3,6-tetrahydro-1-

Absolute stereochemistry.




RN 725261-69-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1,2,3,6-tetrahydro-1-[(1-methylsulfonyl)amino]acetyl)-4-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-70-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-71-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1,1,3,6-tetrahydro-1-imino-1-oxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-72-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1,1,3,6-tetrahydro-1-imino-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-73-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[1,1,3,6-tetrahydro-1-(methylimino)-1-oxido-2H-thiopyran-4-yl]phenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-74-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[1,1,3,6-tetrahydro-1-

Absolute stereochemistry.




RN 725261-75-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[1-(acetylimino)-1,1,3,6-tetrahydro-1-oxido-2H-thiopyran-4-yl]-3-fluorophenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725261-76-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[1-(acetylimino)-1,1,3,6-tetrahydro-1-oxido-2H-thiopyran-4-yl]-3-fluorophenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725261-77-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[1,1,3,6-tetrahydro-1-[(hydroxymethyl)imino]-1-oxido-2H-thiopyran-4-yl]phenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 725261-78-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[1,1,3,6-tetrahydro-1-[(hydroxymethyl)imino]-1-oxido-2H-thiopyran-4-yl]-3-fluorophenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A


PAGE 1-A



RN 725261-80-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 2-A




RN 725261-81-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(2H-pyran-4-yl)phenyl]-N-methyl-2-oxo-, (9CI) (CA INDEX NAME)

RN 725261-79-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-83-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 725261-85-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725261-87-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 726169-59-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(3-hydroxy-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 726169-60-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(3-methoxy-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 726169-61-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3-cyano-3-azabicyclo[3.1.0]hex-6-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 726169-62-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(2-oxo-3-oxabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 726169-63-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(2-oxo-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 726169-64-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(3-methyl-2-oxo-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:333714 CAPLUS
 DOCUMENT NUMBER: 140:357327
 TITLE: Preparation of bicyclic[3.1.0]oxazolidinones and related compounds as antibacterial agents
 INVENTOR(S): Gordiev, Mikhail Fedor; Renzlo, Adam; Patel, Dinesh Vinooobhai
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 156 pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033451	A1	20040422	WO 2003-US28560	20031003
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, T2, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, KK, HU, SK				
US 2004127530	A1	20040701	US 2003-677451	20031002
US 6875784	B2	20050405		
CA 2501352	AA	20040422	CA 2003-2501352	20031003
EP 1549641	A1	20050706	EP 2003-770310	20031003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, KK, HU, SK				
BR 2003015106	A	20050809	BR 2003-15106	20031003
PRIORITY APPN. INFO.:			US 2002-17735P	P 20021009
WO 2003-US28560			WO 2003-0099	
OTHER SOURCE(S): MARPAT 140:357327				20031003

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R2, R3 = H, F; R4, R5 = H, Cl, F, etc.; R6, R7 = H, F, OH, etc.]; R8 = H, F, OH, etc.; A = 5-methyl-2-oxazolidinonyl, 4,5-dihydro-5-Me-2-(3H)-furanonyl, etc.; B = $(CH_2)_n$, n = 0-1; X = N, CH; Y = N, O, S; Z = NHCO, NHCS, NHCR, etc.; R1 = H, NH2, NH-alkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, condensation of CBZ-protected benzanilide II, e.g., prepared from benzyl 3-pyrrolidine-1-carboxylate in 5-steps, and (S)-acetic acid 2-acetylaminoh-1-chloromethyl ethyl ester afforded oxazolidinone III in 62% yield. In S. aureus Min. Inhibitory Concentration (MIC) growth studies, 6-examples of compds. I exhibited MIC values ranging from 1-8 μ g/mL, i.e., the MIC value of oxazolidinone III was 1 μ g/mL. Compds. I are claimed useful for the treatment of skin and eye infections.

IT 681424-71-5P


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)

RN 681424-71-5 CAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carboxylic acid, 3-[4-[(5R)-5-(aminocarbonyl)-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-, (1a,5a,6a)-, mono(trifluoroacetyl) (9CI) (CA INDEX NAME)

CM 1

CRN 681424-70-4
 CMF C16 H15 F2 N3 O5

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



IT 681425-57-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)

RN 681425-57-0 CAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-6-carboxylic acid, 3-[4-[(5R)-5-(aminocarbonyl)-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-, 1,1-dimethyllethyl ester, (1a,5a,6a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:696876 CAPLUS
 DOCUMENT NUMBER: 139:214457
 TITLE: Preparation of 3-aryl-2-oxo-5-oxazolidinecarboxamides and analogs as antibacterial agents
 INVENTOR(S): Thomas, Richard C.; Poel, Toni-Jo; Barbashyn, Michael R.; Gornset, Mikhail F.; Luehr, Gary W.; Renslo, Adams Singh; Upinder
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl. 234 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072553	A1	20030904	WO 2003-US3125	20030224
WO 2003072553	C1	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RD, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2476038 AA 20030904 CA 2003-2476038 20030224 EP 1478629 A1 20041124 EP 2003-743112 20030224 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, HK, CY, AL, TR, BG, CZ, ER, HU, SK BR 2003007924 A 20041207 BR 2003-7924 20030224 JP 2005524660 T2 20050818 JP 2003-571259 20030224 NO 2004004062 A 20041026 NO 2004-4062 20040924 PRIORITY APPLN. INFO.: US 2002-359495P P 20020225 WO 2003-US3125 W 20030224				

OTHER SOURCE(S): MARPAT 139:214457

GI




AB Title compds. of formulae I, II, and III [wherein B = (un)substituted cycloalkyl, cycloalkenyl, aryl, or heterocyclyl; C = (hetero)aryl (un)substituted with 1-3 R₂; or BC = (un)substituted bicyclic heterocycle; R₁ = H, OH, cycloalkyl, NH₂, or (un)substituted alkyl, alkoxy, or alkenyl; R₂ = independently H, halo, NO₂, CN, halo, or (un)substituted alkyl; with provisos: and pharmaceutically acceptable salts thereof] were prepared as antibacterial agents. Examples include syntheses and biol. data for 91 compds. For instance, benzyl 3-fluoro-4-(4-morpholinyl)phenylcarbamate was stirred with BuLi in THF at -78° for 30 min. Cycloaddn. with potassium (2R)-glycidate gave the 2-oxo-5-oxazolidinecarboxylic acid, which was amidated using oxalyl chloride and ammonium to afford (R)-(-)-IV. Compds. of the invention inhibited growth of *Staphylococcus aureus* with MIC values ranging from 0.5 µg/mL to 16 µg/mL. Thus, I, II, and III and their pharmaceutical compns. are useful for the treatment of microbial infections.

IT 487041-12-3P, (5R)-(-)-3-[4-(3,6-Dihydro-2H-pyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-18-9P, (5R)-(-)-3-[4-(3,6-Dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 5,5-dioxide 487041-38-3P, (5R)-(-)-3-[3-Fluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide S-Oxide 487041-40-7P, (5R)-(-)-3-[3,5-Bifluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide S-Oxide 487041-49-5P, (5R)-(-)-3-[4-(4-Oxo-3,4-dihydro-1(2H)-pyridinyl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (antibacterial agent); preparation of aryloxazolidinecarboxamides and analogs as antibacterial agents)


RN 487041-12-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-2H-pyran-4-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-18-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-38-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




Absolute stereochemistry. Rotation (-).



RN 487041-40-7 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
oxooxazolidine-5-carboxamide 590420-89-6P, (5R)-(-)-N-Methyl-3-[3,5-difluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide S-oxide 590420-92-1P 590420-94-3P,
(5R)-3-[3,5-Difluoro-4-(Tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide S,S-dioxide 590421-05-9P
590421-07-1P 590421-09-2P 590421-23-1P,
(5R)-3-[4-(5,7-Dihydro-6H-pyrrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-25-3P, (5R)-N-Methyl-3-[4-(5,7-dihydro-6H-pyrrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-26-4P 590421-31-1P
, (5R)-(-)-3-[3,5-Difluoro-4-[1-(methoxycarbonyl)-3-methylazetidin-3-yl]phenyl]-2-oxooxazolidine-5-carboxamide 590421-40-2P,
(5R)-(-)-N-Methyl-3-[3,5-difluoro-4-[1-(methoxycarbonyl)-3-methylazetidin-3-yl]phenyl]-2-oxooxazolidine-5-carboxamide 590421-49-1P,
(5R)-3-[3-Fluoro-4-(5-oxo-5,6-dihydro-4H-[1,3,4]thiadiazin-2-yl)phenyl]-2-oxooxazolidine-5-carboxamide 590421-57-1P, (5R)-3-[4-(1,1-Dioxido-2,3-dihydro-4H-1,4-thiazin-4-yl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-60-6P, (5R)-3-[4-(2,5-Dihydro-1H-pyrrrol-1-yl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-75-3P, (5R)-N-Methyl-3-[4-(4-oxo-3,4-dihydro-1(H)-pyridinyl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-76-4P, (5R)-N-Ethyl-3-[4-(4-oxo-3,4-dihydro-1(H)-pyridinyl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-77-5P, (5R)-3-[4-(4-Oxo-3,4-dihydro-1(H)-pyridinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590421-83-3P,
(5R)-N-Methyl-3-[4-(4-oxo-3,4-dihydro-1(H)-pyridinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590421-84-4P, (5R)-N-Ethyl-3-[4-(4-oxo-3,4-dihydro-1(H)-pyridinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590421-85-5P, (5R)-N-(2-Fluoroethyl)-3-[4-(4-oxo-3,4-dihydro-1(H)-pyridinyl)phenyl]-2-oxooxazolidine-5-carboxamide 590421-86-6P,
(5R)-3-[4-(4-Oxo-3,4-dihydro-1(H)-pyridinyl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 590421-92-4P, (5R)-N-Methyl-3-[4-(4-oxo-3,4-dihydro-1(H)-pyridinyl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 590422-33-6P 590422-34-7P
590422-35-8P 590422-36-9P 590422-37-0P
590422-38-1P 590422-39-2P 590422-40-5P
590422-41-6P, (5R)-3-[3-Fluoro-4-(1-imino-1-oxido-4-thiomorpholinyl)-2-oxooxazolidine-5-carboxamide
590422-42-7P, (5R)-N-Methyl-3-[3-Fluoro-4-(1-imino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide
590422-43-8P, (5R)-3-[3-Fluoro-4-(1-methylimino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide
590422-44-9P, (5R)-N-Methyl-3-[3-Fluoro-4-(1-methylimino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide
590422-45-0P, (5R)-3-[3,5-Difluoro-4-(1-imino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide
590422-46-1P, (5R)-N-Methyl-3-[3,5-Difluoro-4-(1-imino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide
590422-47-2P, (5R)-3-[3,5-Difluoro-4-(1-methylimino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide
590422-48-3P, (5R)-N-Methyl-3-[3,5-Difluoro-4-(1-methylimino-1-oxido-4-thiomorpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide
590422-55-2P, (5R)-3-[3,5-Difluoro-4-(1-formyl-3-methylazetidin-3-yl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-56-3P,
(5R)-N-Methyl-3-[3,5-difluoro-4-(1-formyl-3-methylazetidin-3-yl)phenyl]-2-




IT 487040-98-2P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 487041-01-0P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 487041-02-1P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-N-allyl-2-oxooxazolidine-5-carboxamide 487041-03-2P,
(5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-N-propyl-2-oxooxazolidine-5-carboxamide 487041-04-3P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-N-methoxy-2-oxooxazolidine-5-carboxamide 487041-07-6P,
(5R)-(-)-3-[4-(3-Pyridyl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-11-2P, (5R)-(-)-3-[4-(4-Pyridyl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-14-5P, (5R)-(-)-3-[4-(Tetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-15-6P,
(5R)-(-)-3-[4-(3,6-Dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-19-0P
, (5R)-(-)-3-[4-(Tetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-20-3P,
(5R)-(-)-3-[3-Fluoro-4-(4-hydroxymethyl)-1-piperazinyl]phenyl]-2-oxooxazolidine-5-carboxamide 487041-26-9P, (5R)-(-)-3-[4-(Thiomorpholin-4-yl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-28-1P, (5R)-(-)-3-[3,5-Difluoro-4-(4-morpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 487041-31-6P,
(5R)-(-)-3-[4-(Thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 487041-34-7P, (5R)-(-)-3-[3-Fluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 487041-45-2P, (5R)-(-)-3-[4-(Tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 487042-08-4P,
(5R)-(-)-3-[4-Methyl-3-[4-(Tetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487042-31-7P, (5R)-(-)-3-[4-(3-Fluoro-4-(4-yl)phenyl)-2-oxooxazolidine-5-carboxamide 487042-35-0P, (5R)-(-)-3-[3-Fluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 487042-45-2P, (5R)-(-)-3-[4-(Tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 487042-58-5P,
(5R)-(-)-3-[4-(3-Fluoro-4-(4-yl)phenyl)-2-oxooxazolidine-5-carboxamide 487042-87-4P, (5R)-(-)-3-[4-(3-Fluoro-4-(4-yl)phenyl)-2-oxooxazolidine-5-carboxamide 487042-88-5P,
(5R)-(-)-N-Methyl-3-[3,5-difluoro-4-(4-morpholinyl)phenyl]-2-

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
oxooxazolidine-5-carboxamide 590422-57-4P, (5R)-3-[3-Fluoro-4-(1-formyl-3-methylazetidin-3-yl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-58-5P, (5R)-N-Methyl-3-[3-fluoro-4-(1-formyl-3-methylazetidin-3-yl)phenyl]-2-oxooxazolidine-5-carboxamide 590422-71-2P 590422-72-3P 590422-73-4P

590422-74-5P 590422-75-6P 590422-76-7P
590422-77-8P 590422-78-9P 591233-29-3P
591233-31-7P 591233-33-9P 591233-35-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (antibacterial agent; prepn. of aryloxazolidinecarboxamides and analogs as antibacterial agents)


RN 487040-98-2 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-01-0 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-N-methyl-2-

Absolute stereochemistry. Rotation (-).




RN 487041-02-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-N-2-propenyl-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-03-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-N-propyl-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-04-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-N-methoxy-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-05-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-N-hydroxy-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-07-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(3-pyridinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-11-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-pyridinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-14-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(tetrahydro-2H-pyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-15-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 487041-19-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-20-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)




RN 487041-26-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-(4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl)-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-28-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(4-morpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-31-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-35-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-45-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 2-oxo-3-[4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590420-87-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590420-88-5 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(4-morpholinyl)phenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590420-89-6 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590420-92-1 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590420-94-3 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-05-9 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590421-07-1 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590421-09-3 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-23-1 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-25-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(5,7-dihydro-6H-pyrido[3,4-b]pyridin-6-yl)-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-26-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(cis-tetrahydro-1-imino-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-31-1 CAPLUS
 CN 1-Azetidinecarboxylic acid, 3-[4-((5R)-5-(aminocarbonyl)-2-oxo-3-oxazolidinyl)-2,6-difluorophenyl]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590421-40-2 CAPLUS
 CN 1-Azetidinecarboxylic acid, 3-[2,6-difluoro-4-((5R)-5-(methylamino)carbonyl)-2-oxo-3-oxazolidinyl]phenyl]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 590421-49-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(5,6-dihydro-5-oxo-4H-1,3,4-thiadiazin-2-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 590421-60-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(2,5-dihydro-1H-pyrrol-1-yl)-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-75-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-3-fluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 590421-57-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(2,3-dihydro-1,1-dioxido-4H-1,4-thiazin-4-yl)-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-76-4 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-3-fluorophenyl]-N-ethyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-77-5 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)phenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)




RN 590421-83-3 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)phenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-84-4 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)phenyl]-N-ethyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-85-5 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)phenyl]-N-(2-fluoroethyl)-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-86-6 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-3,5-difluorophenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-92-4 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-3,5-difluorophenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-93-5 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-3,5-difluorophenyl]-N-ethyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590421-94-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[3,4-dihydro-4-(hydroxymino)-1(2H)-pyridinyl]-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 590422-10-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-

Absolute stereochemistry.




RN 590422-32-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(cis-1,1,3,4,5,6-hexahydro-1-methylimino)-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-33-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(cis-1,1,3,4,5,6-hexahydro-1-imino-1-oxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-34-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(cis-1,1,3,4,5,6-hexahydro-1-methylimino)-1-oxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-35-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(trans-1,1,3,4,5,6-hexahydro-1-imino-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-36-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(trans-1,1,3,4,5,6-hexahydro-1-imino-1-oxido-2H-thiopyran-4-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 590422-37-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[trans-1,1,3,4,5,6-hexahydro-1-(methylimino)-1-oxido-2H-thiopyran-4-yl]phenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 590422-38-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[trans-1,1,3,4,5,6-hexahydro-1-(methylimino)-1-oxido-2H-thiopyran-4-yl]phenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 590422-39-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 590422-40-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3,5-difluorophenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



RN 590422-41-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-imino-1-oxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 590422-43-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-(methylimino)-1-oxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-44-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-(methylimino)-1-oxido-4-thiomorpholinyl)-3-fluorophenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 590422-42-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-imino-1-oxido-4-thiomorpholinyl)-3-fluorophenyl]-N-methyl-2-oxo-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-45-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-imino-1-oxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-46-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-imino-1-oxido-4-thiomorpholinyl)-3,5-difluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-55-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-(3,5-difluoro-4-(1-formyl-3-methyl-3-azetidinyl)phenyl)-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-56-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(1-formyl-3-methyl-3-azetidinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-47-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-(methylimino)-1-oxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 590422-48-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dihydro-1-(methylimino)-1-oxido-4-




RN 590422-57-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1-formyl-3-methyl-3-azetidinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 590422-58-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1-formyl-3-methyl-3-azetidinyl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 590422-71-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-[(2S)-2-hydroxy-1-oxo-3-(phosphonoxy)propyl]-4-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

RN 590422-72-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-[(2S)-2-hydroxy-1-oxo-3-(phosphonoxy)propyl]-4-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 2-A

RN 590422-73-4 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[1-(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 2-A



PAGE 1-A



RN 590422-74-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-[1-(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 590422-75-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-[(2S)-2-hydroxy-1-oxo-3-(phosphonoxy)propyl]-4-pyridinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A



RN 590422-76-7 CAPLUS



CN 5-Oxazolidinecarboxamide, 3-(3-fluoro-4-[(2S,3S,6S)-2,3,6-tetrahydro-1-oxo-2-hydroxy-4-oxo-3-(phosphonoxy)propyl]-4-pyridinyl)-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 590422-77-8 CAPLUS

CN 5-Oxazolidinecarboxamide, 3-[4-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 590422-78-9 CAPLUS


CN 5-Oxazolidinecarboxamide, 3-[4-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 591233-29-3 CAPLUS


CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 591233-31-7 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 591233-33-9 CAPLUS
CN 5-Oxazolidinecarboxamide, 2-oxo-3-[4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
oxazolidine-5-carboxamide 487041-21-4P, (-)-Phenylmethyl 4-[4-((5R)-5-(aminocarbonyl)-2-oxo-3-oxazolidinyl)-2-fluorophenyl]-1-piperazinecarboxylate 487041-24-7P, (5R)-3-[3-Fluoro-4-[4-((phenylmethoxy)acetyl)-1-piperazinyl]phenyl]-2-oxazolidine-5-carboxamide 487041-25-8P, (5R)-3-[3-Fluoro-4-(piperazin-1-yl)phenyl]-2-oxazolidine-5-carboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate/ prep. of arylazolidinecarboxamides and analogs as antibacterial agents)
RN 487041-06-5 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-N-(phenylmethoxy)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-17-8 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 591233-35-1 CAPLUS
CN 5-Oxazolidinecarboxamide, 2-oxo-3-[4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 487041-06-5P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-N-benzyl-2-oxazolidine-5-carboxamide 487041-17-8P, (5R)-(-)-3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-




RN 487041-21-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-((5R)-5-(aminocarbonyl)-2-oxo-3-oxazolidinyl)-2-fluorophenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-24-7 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[4-(phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 487041-25-8 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-,
(5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
prepd. starting from II and III, followed by N-acylation and hydrogenation. In addn. to the presence of the phosphonoxy group in compds. I, also claimed are compds. I contg. an acyloxy group. The bioavailability of these oxazolidinones is improved by improving the solv. thereof. Also included in the examples are preps. of .apprx.25 amide-contg. oxazolidinones, from which compds. I can potentially be prepd.

IT 487040-98-2P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 487041-01-0P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-N-allyl-2-oxooxazolidine-5-carboxamide 487041-02-2P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-N-propyl-2-oxooxazolidine-5-carboxamide 487041-04-3P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-N-methoxy-2-oxooxazolidine-5-carboxamide 487041-05-4P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-N-hydroxy-2-oxooxazolidine-5-carboxamide 487041-06-5P, (5R)-(-)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-N-benzyloxy-2-oxooxazolidine-5-carboxamide 487041-07-6P, (5R)-(-)-3-[4-(3-Pyridyl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-11-2P, (5R)-(-)-3-[4-(4-Pyridyl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-12-3P, (5R)-(-)-3-[4-(3,6-Dihydro-2H-pyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-14-5P, (5R)-(-)-3-[4-(Tetrahydro-2H-pyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-15-6P, (5R)-(-)-3-[4-(3,6-Dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-18-9P, (5R)-(-)-3-[4-(3,6-Dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-19-0P, (5R)-(-)-3-[4-(Tetrahydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-20-3P, (5R)-(-)-3-[3-Fluoro-4-(4-hydronaphthyl)-1-piperazinyl]phenyl]-2-oxooxazolidine-5-carboxamide 487041-21-4P, (-)-Phenylmethyl-4-[4-(5-(aminocarbonyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl]-1-piperazinocarboxylate 487041-24-7P, (5R)-3-[3-Fluoro-4-[4-(phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-2-oxooxazolidine-5-carboxamide 487041-25-8P, (5R)-3-[3-Fluoro-4-piperazinophenyl]-2-oxooxazolidine-5-carboxamide 487041-26-9P, (5R)-(-)-3-[4-(Thiomorpholin-4-yl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 487041-28-1P, (5R)-(-)-3-[3,5-Difluoro-4-(4-morpholinyl)phenyl]-2-oxooxazolidine-5-carboxamide 487041-31-6P, (5R)-(-)-3-[4-(Thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 487041-35-0P, (5R)-(-)-3-[3-Fluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 487041-38-3P, (5R)-(-)-3-[3-Fluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 487041-40-7P, (5R)-(-)-3-[3,5-Difluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxooxazolidine-5-carboxamide 487041-45-2P, (5R)-(-)-3-[4-(Tetrahydro-2H-thiopyran-4-yl)-3,5-difluorophenyl]-2-oxooxazolidine-5-carboxamide 488097-36-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation for potential conversion to more water-soluble and bioavailable
derivs. containing acyloxy or phosphonoxy functionality)

RN 487040-98-2 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-,
(5R)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003-58066 CAPLUS
DOCUMENT NUMBER: 138-112415
TITLE: Preparation of amide-containing oxazolidinones having improved solubility and bioavailability
INVENTOR(S): Hester, Jackson B., Jr.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 331 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006440	A2	20030123	WO 2002-0522526	20020712
WO 2003006440	C1	20030710		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZW	RV: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AH, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CR, CY, CZ, DE, DK, ER, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, MR, NE, SN, TD, TG	CA 2452513	AA 20030123	CA 2002-2452513
US 2004014967	A1	20040122	US 2002-194914	20020712
EP 1451164	A2	20040901	EP 2002-752358	20020712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, KE	JP 2005520782	T2 20050714	JP 2003-512212	20020712
PRIORITY APPLN. INFO.:			US 2001-304808P	P 20010712
OTHER SOURCE(S):			WO 2002-0522526	W 20020712
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention is directed to amide-containing oxazolidinones (1) which have an improved solubility (no data) and a method of improving the solubility of amide-containing oxazolidinone bactericides. A very broad range of compds.


1 is claimed (see claims for details). Also claimed is method of conversion of amide-containing oxazolidinones to more water-soluble derivs. comprising reaction with 3-(2-(dipropoxypyrophosphoryl)oxy)-4,6-dimethylphenyl-3-methylbutanoyl chloride to form a C(O)NRC(O) or C(O)NRC(S) linkage followed by deprotection to give a phosphoric acid monoester. However, the only example is somewhat different in that I is

Absolute stereochemistry. Rotation (-).




RN 487041-01-0 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-N-methyl-2-

Absolute stereochemistry. Rotation (-).




RN 487041-02-1 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-N-2-

Absolute stereochemistry. Rotation (-).




RN 487041-03-2 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-N-propyl-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-04-3 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-N-methoxy-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-05-4 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-N-hydroxy-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-06-5 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-N-(phenylmethoxy)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-07-6 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(3-pyridinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-11-2 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(4-pyridinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-12-3 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-2H-pyran-4-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-14-5 CAPLUS
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(tetrahydro-2H-pyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-15-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 487041-17-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-18-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-19-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-20-3 CAPLUS
 CN 5-Oxazolidinecarboxamides, 3-[3-fluoro-4-[4-(hydroxymethyl)-1-piperazinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 487041-21-4 CAPLUS
 CN 1-Piperazinylcarboxylic acid, 4-[(5R)-5-(aminocarbonyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 487041-24-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[4-[(phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 487041-25-8 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1-piperazinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 487041-26-9 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-4-thiomorpholinyl)-3,5-difluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 487041-28-1 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(4-morpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 487041-31-6 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 487041-35-0 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[4-(1,1-dioxido-4-thiomorpholinyl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 487041-38-3 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 487041-40-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-(1-oxido-4-thiomorpholinyl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 487041-45-2 CAPLUS
 CN 5-Oxazolidinecarboxamide, 2-oxo-3-[4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 488097-36-5 CAPLUS
 CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 488097-38-7 CAPLUS
 CN 5-Oxazolidinecarboxamide, 2-oxo-3-[4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 1996-288283 CAPLUS
 124:317142
 Preparation of N-phenyl-2-oxooxazolidine-5-carboxylates as bioadhesion inhibitors
 Jurassyk, Horst; Gante, Joachim; Wurziger, Hanns;
 Bernotat-Danielowski, Sabine; Melzer, Guido
 Merck Patent Gmbh, Germany
 Eur. Pat. Appl., 24 pp.

PATENT ASSIGNEE(S):
 SOURCE: CODEN: EPXADW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 697408	A1	19960221	EP 1995-112593	19950810
EP 697408	B1	20020123		
DE 4429461	A1	19960222	DE 1994-4429461	19940819
IV 425392	B	20010311	IV 1995-84106938	19950705
AT 212339	E	20020215	AT 1995-112583	19950810
PT 697408	I	20020731	PT 1995-112583	19950810
ES 2170114	I3	20020801	ES 1995-112583	19950810
SK 281754	B6	20010710	SK 1995-1001	19950811
AU 9528522	A1	19960229	AU 1995-28522	19950814
AU 698412	B2	19980129		
CZ 290984	B6	20021113	CZ 1995-2087	19950815
CA 2156360	AA	19960220	CA 1995-2156360	19950817
CN 1125575	A	19960703	CN 1995-115286	19950817
HU 76790	A2	19971128	HU 1995-2431	19950817
NO 9503253	A	19960220	NO 1995-3253	19950818
ZA 9506929	A	19960329	ZA 1995-6929	19950818
JP 08092227	A2	19960409	JP 1995-232106	19950818
US 5614535	A	19970325	US 1995-516937	19950818
RU 2156765	C2	20000927	RU 1995-113863	19950818
PL 182615	B1	20020228	PL 1995-310070	19950818

PRIORITY APPLN. INFO.: MARPAT 124:317142
 OTHER SOURCE(S): GI



AB Title compd. [I; R = OH, alkoxy, N-attached heterocycl, etc.; R1 = NO2, (di)(alkyl)amino, cyano, acyl, etc.] were prepared as bioadhesion inhibitors (no data). Thus, I (R = Cl, R1 = 4-cyano) was amidated by benzyl piperazine-1-acetate to give title compound II.


IT 176370-84-6P 176370-85-7P 176370-86-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of N-phenyl-2-oxooxazolidine-5-carboxylates as bioadhesion inhibitors)

RN 176370-84-6 CAPLUS


CN D-Alanine, N-[(3-[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 176370-85-7 CAPLUS
 CN D-Alanine, N-[(3-[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 176370-86-8 CAPLUS
 CN D-Aspartic acid, N-[(3-[4-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl]carbonyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 176370-87-9 CAPLUS
 CN D-Aspartic acid, N-[(3-[4-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 176370-88-0 CAPLUS
 CN D-Aspartic acid, N-[(3-[4-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 176371-57-6 CAPLUS
CN β-Alanine, N-[3-[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]-2-oxo-5-oxazolidinyl]carbonyl- (9CI) (CA INDEX NAME)



10646440 1/08/06

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
--	---------------------	------------------

FULL ESTIMATED COST

31.58

198.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
--	---------------------	------------------

CA SUBSCRIBER PRICE

-4.50

-4.50

STN INTERNATIONAL LOGOFF AT 08:16:00 ON 23 JAN 2006